Literature DB >> 6582294

Abnormal response of tumor vasculature to vasoactive drugs.

R C Chan, C F Babbs, R J Vetter, C H Lamar.   

Abstract

The effects of the vasoconstrictor phenylephrine and the vasodilator hydralazine on blood flow to tumor were studied and compared to those on blood flow to normal tissues in vivo. Regional blood flow and cardiac output were measured with the use of radioactive microspheres in 150- to 250-g inbred Harlan F344 rats bearing subcutaneous nodules of two types of transplantable carcinoma ("hard" and "soft") with microscopically different vascular patterns. Three groups of rats were treated with hydralazine, saline, or phenylephrine, and regional blood flow was determined at the time of maximum blood pressure response. Results were correlated with quantitative morphometric analysis of arteriolar and capillary wall thickness in tumor and normal tissue. Phenylephrine decreased and hydralazine increased normal tissue perfusion as indicated by cardiac output. Tumor blood flow remained low and was not significantly influenced by drug treatment, except for the phenylephrine effect on hard tumors. Histologic study of tumor vessel walls revealed an absence of smooth muscle capable of responding to the vasoactive drugs by constriction or dilation. Evidently, by their selective action on normal vessels, vasoactive drugs can change the ratio of tumor:normal tissue perfusion. In particular, the increase of normal tissue: tumor blood flow by vasodilator drugs may enhance the selectivity of local heat therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6582294     DOI: 10.1093/jnci/72.1.145

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  19 in total

1.  Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model.

Authors:  Danielle J McCullough; Linda M-D Nguyen; Dietmar W Siemann; Bradley J Behnke
Journal:  J Appl Physiol (1985)       Date:  2013-10-31

Review 2.  Animal models for exploring the pharmacokinetics of breast cancer therapies.

Authors:  Omar M Rashid; Kazuaki Takabe
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-11-21       Impact factor: 4.481

3.  Radiofrequency ablation: post-ablation assessment using CT perfusion with pharmacological modulation in a rat subcutaneous tumor model.

Authors:  Hanping Wu; Agata A Exner; Tianyi M Krupka; Brent D Weinberg; Ravi Patel; John R Haaga
Journal:  Acad Radiol       Date:  2009-03       Impact factor: 3.173

4.  Vasomodulation of tumor blood flow: effect on perfusion and thermal ablation size.

Authors:  Hanping Wu; Agata A Exner; Tianyi M Krupka; Brent D Weinberg; John R Haaga
Journal:  Ann Biomed Eng       Date:  2008-12-16       Impact factor: 3.934

Review 5.  Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Authors:  Yuko Nakamura; Ai Mochida; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

6.  Effects of tumour cells on angiogenesis and vasoconstrictor responses in sponge implants in mice.

Authors:  S P Andrade; Y S Bakhle; I Hart; P J Piper
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

7.  Modification of the 31P magnetic resonance spectra of a rat tumour using vasodilators and its relationship to hypotension.

Authors:  G M Tozer; R J Maxwell; J R Griffiths; P Pham
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

8.  An examination of the influence of vasoactive drugs on blood flow and localisation of a monoclonal antibody in human tumour xenografts.

Authors:  M V Pimm
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

9.  Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life.

Authors:  Hemant Sarin; Ariel S Kanevsky; Steve H Fung; John A Butman; Robert W Cox; Daniel Glen; Richard Reynolds; Sungyoung Auh
Journal:  J Transl Med       Date:  2009-05-13       Impact factor: 5.531

10.  The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours.

Authors:  I A Burney; R J Maxwell; J R Griffiths; S B Field
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.